Laboratoris Sanifit S.L., a Palma de Mallorca, Spain-based clinical-stage biopharmaceutical company, raised €36.6M (approx. $41M) in Series C financing.
The round was led by Ysios Capital with participation from new investors Lundbeckfond Ventures, Forbion Capital Partners, Gilde Healthcare, Edmond de Rothschild Investment Partners, ‘la Caixa’ and Baxter Ventures as well as existing shareholders.
The company intends to use the funds to advance its lead drug candidate, SNF472, through phase IIb proof of concept for the treatment of cardiovascular diseases linked to calcification in ESRD and to complete phase II/III for calciphylaxis.
Led by Joan Perelló, CEO, Laboratoris Sanifit is focused on the development of SNF472, an experimental drug for the treatment of cardiovascular diseases linked to calcification in patients with End Stage Renal Disease (ESRD) undergoing haemodialysis.
SNF472 has shown efficacy data in more than 20 preclinical studies. It has also shown safety and tolerability in a phase Ia clinical trial in healthy volunteers.
It is currently concluding a phase Ib/IIa pharmacology study in haemodialysis patients.
In addition to the funding, Sanifit appointed Dr. Russell Greig as chairman of the board of directors. Dr. Greig worked at GSK for nearly three decades, most recently as president of SR One, GSK’s Corporate Venture Group. Prior to joining SR One, he served as president of GSK’s Pharmaceuticals International and was on the corporate executive team from 2003 to 2008.